Scientific Article
previous document  unige:9382  next document
add to browser collection

Antibiothérapie empirique lors de neutropénie fébrile

Kridel, R.
Calandra, T.
Marchetti, O.
Published in Revue médicale suisse. 2008, vol. 4, no. 152, p. 914, 916-919
Abstract Immediate broad-spectrum empirical antibacterial therapy is the key of management in febrile neutropenic patients. These patients can be stratified according to the risk of complications with the clinical MASCC score. Patients at low risk of complications can be efficaciously treated with oral antibiotics (e.g. fluoroquinolone and beta-lactam), provided that compliance and drug absorption are adequate. Early discharge is possible if clinical, logistic, and social criteria are fulfilled. Intravenous antibiotic therapy with broad-spectrum beta-lactam antibiotics in the hospital remains the standard in high-risk patients. The empirical addition of an aminoglycoside and/or a glycopeptide is recommended if the local incidence of infections due to beta-lactam resistant pathogens is high or in critically ill septic patients.
Keywords Anti-Bacterial Agents/ therapeutic useFever/ drug therapyHumansNeutropenia/ drug therapyPatient DischargePatient Selection
PMID: 18578432
Full text
This document has no fulltext available yet, but you can contact its author by using the form below.
(ISO format)
KRIDEL, R. et al. Antibiothérapie empirique lors de neutropénie fébrile. In: Revue médicale suisse, 2008, vol. 4, n° 152, p. 914, 916-919.

348 hits

0 download


Deposited on : 2010-07-12

Export document
Format :
Citation style :